Astrin Biosciences, a company focused on transforming cancer detection and treatment through advanced proteomics and artificial intelligence, announced the establishment of its Scientific Advisory Board. The board brings together leading experts in women’s health and cancer research to help guide Astrin’s mission of detecting cancer at its earliest and most treatable stages.
Health Technology Insights: Owkin Launches Europe’s First Pan-European Biology AI Platform
“Our goal at Astrin is to expand what is possible in early cancer detection,” said Jayant Parthasarathy, PhD, CEO of Astrin Biosciences. “We believe that identifying cancer at Stage 0 should become routine. This board includes remarkable scientific and clinical leaders who share that vision and will help us translate breakthrough technologies into practical clinical applications.”
Health Technology Insights: Trilliant Health Simplifies Hospital Price Transparency Access
The Scientific Advisory Board features prominent researchers and clinicians, including Adrian V. Lee, PhD, a Professor at the University of Pittsburgh known for his work in the cellular and molecular biology of breast cancer; Barbara Levy, MD, FACOG, FACS, MSCP, Chief Medical Officer at Visana Health and Clinical Professor at George Washington University and UC San Diego Health; Ben H. Park, MD, PhD, Director of the Vanderbilt-Ingram Cancer Center and expert in cancer genetics and liquid biopsy; Julio Aguirre-Ghiso, PhD, Professor of Cell Biology and Founding Director of the Cancer Dormancy Institute at Albert Einstein College of Medicine; Nilay Sethi, MD, PhD, a Physician-Scientist at Dana-Farber Cancer Institute and Assistant Professor at Harvard Medical School; Pooja P. Advani, MD, Medical Oncologist and Director of the Multidisciplinary Breast Clinic at Mayo Clinic in Jacksonville; Thomas Gilbert, MD, Radiologist and Chief Clinical Officer at RAYUS Radiology; and William G. Morice II, MD, PhD, President and CEO of Mayo Clinic Laboratories and Mayo Collaborative Services.
The creation of this board follows Astrin’s recent launch of Certitude Breast, the first non-imaging screening test designed to detect breast cancer as early as stage 0. By combining expertise in AI, proteomics, and clinical research, Astrin aims to accelerate the adoption of early detection tools that can improve outcomes and provide patients with actionable insights sooner.
The board will work closely with Astrin’s research teams to advise on clinical validation, product development, and translational studies, ensuring that innovations move from the laboratory to real-world application effectively. With this strategic advisory team in place, Astrin is positioned to strengthen its leadership in early cancer detection and shape the future of precision diagnostics.
Health Technology Insights: Health Systems Struggle to Manage Growing AI Project Demand
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
